Affording the Future Mix of Medication Therapies
With some biologic medications costing $100,000 or more annually, to treat a patient with a serious chronic illness, how will payers and patients afford the accelerating shift towards biologics?
Dramatic increases ahead for spending on biologics.
Randy Vogenberg, RPh, PhD, noted consultant, author, and executive director of the Biologic Finance & Access Council Program at Philadelphia’s Thomas Jefferson University’s School of Population Health discusses how payers’ benefit design strategies may help more patients afford costly biologics and specialty medication therapies for chronic … Continue Reading
Play to listen or right-click on the podcast's title (above) to download.